ArticleHead & neck2026
TNFRSF1A (-135 T>C, rs767455) Polymorphism as a Predictor of Radiation Induced Oral Mucositis and Treatment Response in Locally Advanced Head and Neck Cancer Patients.
Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionHead and neck squamous cell carcinoma (HNSCC) is the most common head and neck cancer in India, where intensity-modulated radiation therapy (IMRT) is the standard treatment. Despite therapeutic advances, variability in radiation response and toxicities persists. Genetic factors, including the TNFRSF1A (-135 T>C, rs767455) polymorphism, may influence susceptibility to oral mucositis, dermatitis, and treatment response, but remain insufficiently studied in Indian populations. Functional validation through serum TNF-α profiling and predictive modeling is also lacking.
methodsA total of 50 patients with locally advanced HNSCC were treated with IMRT (70 Gy/35 fractions) and weekly cisplatin (40 mg/m
resultsGenotype distribution was TT (52.0%), TC (38.0%), and CC (10.0%). Carriers of the C allele (TC/CC) had a significantly higher risk of severe mucositis (OR = 4.58, p = 0.010), while no association was observed with dermatitis. The TT genotype correlated with complete response (OR = 7.00, p = 0.002) and higher median serum TNF-α levels (13.28 pg/mL, p = 0.041). Multivariate analysis confirmed TNFRSF1A genotype as an independent predictor of mucositis and response, while age was protective against dermatitis. The Random Forest model achieved 60% accuracy in predicting treatment response.
conclusionThe TNFRSF1A (-135 T>C) polymorphism influences both toxicity and response in HNSCC, with the C allele predisposing to mucositis and the TT genotype predicting favorable outcomes. It represents a potential biomarker for personalized radiotherapy, meriting validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.